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Edited by Sandro SonninoAbstract Arachidonic acid (AA) regulates many aspects of vas-
cular smooth muscle behaviour, but the mechanisms linking
receptors to AA release are unclear. In A7r5 vascular smooth
muscle cells pre-labelled with 3H-AA, vasopressin caused a con-
centration-dependent stimulation of 3H-AA release that required
phospholipase C and an increase in cytosolic [Ca2+]. Ca2+ re-
lease from intracellular stores and Ca2+ entry via L-type chan-
nels or the capacitative Ca2+ entry pathway were each eﬀective
to varying degrees. Selective inhibitors of PLA2 inhibited the
3H-AA release evoked by vasopressin, though not the underlying
Ca2+ signals, and established that cPLA2 mediates the release of
AA. We conclude that in A7r5 cells vasopressin stimulates AA
release via a Ca2+-dependent activation of cPLA2.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In most cells, stimulation of phospholipase C (PLC) usually
causes both inositol 1,4,5-trisphosphate (IP3)-evoked release
of Ca2+ from intracellular stores and Ca2+ entry across the plas-
mamembrane. The resulting increase in cytosolic free Ca2+ con-
centration ([Ca2+]i) can then regulate an enormous diversity of
cellular processes. Capacitative Ca2+ entry (CCE), activated by
empty Ca2+ stores [1], provides a major route for Ca2+ entry,
but other non-capacitative Ca2+ entry (NCCE) pathways,
includingmany regulated by signals derived from diacylglycerol
(DAG) are also important [2,3]. Both CCE and NCCE contrib-
ute to the Ca2+ entry evoked by Arg8-vasopressin (AVP) inAbbreviations: AA, arachidonic acid; 2-APB, 2-aminoethoxydiphenyl
borane; AVP, Arg8-vasopressin; BAPTA, 1,2-bis(2-aminophenoxy)eth-
ane-N,N,N0N0-tetraacetic acid; [Ca2+]i, intracellular free [Ca
2+]; CCE,
capacitative Ca2+ entry; cPLA2, cytosolic PLA2; DAG, diacylglycerol;
EC50, concentration causing 50% of the maximal response; IC50, con-
centration causing 50% of maximal inhibition; iPLA2, Ca
2+-indepen-
dent PLA2; IP3, inositol 1,4,5-trisphosphate; NCCE, non-capacitative
Ca2+ entry; PA, phosphatidic acid; PC, phosphatidylcholine; PE,
phosphatidylethanolamine; PKC, protein kinase C; PLA2, phospholi-
pase A2; PLC, phospholipase C; PLD, phospholipase D
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doi:10.1016/j.febslet.2006.06.055A7r5 vascular smooth muscle cells, although their relative roles
may diﬀer under diﬀerent conditions [4–9], inﬂuenced by both
the pattern of expression of TrpC proteins [7,10] and the nature
of the stimulus [7]. It is, however, clear that in A7r5 cells, as in
many other cells [11–13], arachidonic acid (AA) contributes to
the coordinate regulation of CCE and NCCE [5,6,14]. In
A7r5 cells, the AA that regulates Ca2+ entry is released from
DAG by DAG lipase [5,6], whereas in other cells it is provided
by the action of phospholipase A2 (PLA2) on phospholipids
[11,15] or by PLA2 and DAG lipase [16]. In addition, very
low concentrations of AVP stimulate Ca2+ entry via L-type
Ca2+ channels in A7r5 cells via a signalling sequence that in-
volves activation of phospholipase D (PLD) [17], stimulation
of protein kinase C (PKC), a src-family kinase and PYK2. This
culminates in phosphorylation of a K+ channel, depolarization,
and opening of L-type Ca2+ channels [18].
In addition to its role in regulating Ca2+ entry, AA is the
source of eiconsanoids, many of which regulate cell growth
and survival [19] and vascular tone [20]. AA also regulates other
ion channels [21], PKC and PLCc [22]; and it sensitizes the con-
tractile machinery of vascular smooth muscle to Ca2+ [23]. It is
important to understand the mechanisms responsible for recep-
tor-mediated release of AA in vascular smooth muscle.
The V1A-AVP receptors of A7r5 vascular smooth muscle
cells stimulate an initial activation of PLC and a more delayed
activation of PLD and PLA2 [14,17] but see [24]. The relation-
ships between these events are not entirely clear: Gq links the
V1A receptor to activation of PLC, but the role of these initial
events in the activation of PLD and PLA2, each of which can
lead to release of AA, is unresolved. Indeed, in both A7r5 cells
and primary aortic smooth muscle [17], persuasive evidence
suggests that AVP can activate PLA2 [25–27] and PLD [17]
independent of its eﬀects on PLC. The present study was
undertaken to measure directly the eﬀects of AVP on AA
production in A7r5 cells.2. Materials and methods
2.1. Measurement of 3H-AA release
A7r5 cells (originally from the American Type Culture Collection)
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum, 3.8 mM L-glutamine and
0.9% non-essential amino acids [28]. For 3H-AA release assays, cells
grown to 70% conﬂuence in 35-mm dishes were incubated for 24 h
in medium containing 0.1% fetal bovine serum and supplemented with
3H-AA (1 lCi/ml). Immediately before an experiment, cells were
washed (4 · 1 ml) with Hepes-buﬀered saline (HBS: 135 mM NaCl,
5.9 mM KCl, 1.2 mM MgCl2, 1.5 mM CaCl2, 11.5 mM glucose, pHblished by Elsevier B.V. All rights reserved.
Y. Liu, C.W. Taylor / FEBS Letters 580 (2006) 4114–4120 41157.3) and then at 1-min intervals for 4 min. The medium bathing the
cells (1 ml) was then removed (for determination of 3H-AA content)
and replaced (1 ml) at intervals of 1-min. All experiments were per-
formed at 20 C; the same temperature was used for analyses of
AVP-evoked Ca2+ signals [4–8]. At the end of each experiment,
Triton-X-100 (1%) was added to lyze the cells, and the medium was re-
moved to determine its 3H-AA content. Because only a small fraction
of the total 3H-AA content of the cells was released during stimulation
(<0.5%/min), it was essential to centrifuge all samples of medium
(18700 · g, 1 min) to remove the very small number of detached cells
before determining the 3H content of the medium by liquid scintillation
counting (800 ll medium in 5 ml Ecoscint A scintillation cocktail).
Fractional rates of 3H-AA release were calculated for each 1-min inter-
val by expressing the amount of 3H released during that interval as a
fraction of the 3H-content remaining within the cells at the beginning
of that interval.
The authenticity of the 3H-AA released from the cells was veriﬁed
using thin-layer chromatography and the solvent systems described
in Irvine et al. [29]. Brieﬂy, samples were adjusted to pH 3 using
HCl, extracted twice with diethyl ether, dried, dissolved in chloroform
and spotted onto a thin-layer chromatography plate (20 cm2 60F-2540
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Fig. 1. AVP-evoked release of 3H-AA. (A) Thin-layer chromatography was
from A7r5 cells labelled with 3H-AA and then treated for 1 min without (ii
positions of standard compounds are shown. (B) 3H-AA release without stimu
or 9 min (s). (C) Concentration-dependent eﬀect of AVP on the peak rate of
(h) or in the presence of U73122 (1 lM, j). (E) 3H-AA release evoked by AV
s). Nimodipine (100 nM) was included in D and E to inhibit L-type Ca2+ cMerck). The plate was developed to 10 cm from the origin with the ﬁrst
solvent system (chloroform:methanol:water:ammonia solution,
70:30:3:2), dried under nitrogen and then developed in the second sol-
vent system (ethyl acetate:acetone:water:glacial acetic acid, 40:40:2:1).
Samples (1 cm long) were then scraped from the dried plate for liquid
scintillation counting.
Concentration eﬀect relationships were analyzed by ﬁtting results to
4-parameter logistic equations using Prism software (GraphPad).
2.2. Measurement of [Ca2+]i
A7r5 cells grown on 96-well plates were loaded with ﬂuo 4 and ﬂuo-
rescence measured using a FlexStation automated ﬂuorescence plate
reader and then calibrated to [Ca2+]i as reported previously [28].
2.3. Materials
3H-AA (209 Ci/mmol) was from Amersham Pharmacia Biotech.
Ionomycin and U73122 (1-[6-((17b-3-methoxyestra-1,3,5(10)-trien-17-
yl)amino)hexyl)-1H-pyrrole-2,5-dione were from Calbiochem. Nimo-
dipine and 2-aminoethoxydiphenyl borane (2-APB) were from Tocris.
AACOCF3 (arachidonyltriﬂuoromethyl ketone), BEL (E-6-bromoeth-0 5 10 15
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used to separate the 3H-labelled components of the medium isolated
) or with AVP (i, 1 lM, 1 min). Results shown as % of recovered 3H;
lation (d) and during stimulation with AVP (1 lM, bars) for 3 min (j)
3H-AA release. (D) 3H-AA release evoked by AVP (100 nM, bar) alone
P (100 nM, bar) alone (d) or in the presence of RHC-80267 (150 lM,
hannels. Results are means ± S.E.M., n = 3 (A, C–E) or 4 (B).
4116 Y. Liu, C.W. Taylor / FEBS Letters 580 (2006) 4114–4120ylene)tetrahydro-3-(1-napthalenyl)-2H-pyran-2-one and ONO-RS-082
(2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid) were from Biomol.
BAPTA-AM and Pluronic F-127 were from Invitrogen. Thapsigargin
was from Alamone Laboratories. AA, verapamil and AVP were from
Sigma. Other materials are listed in previous publications [6–8].3. Results
AVP caused a concentration-dependent (EC50 = 3.2 ±
0.6 nM) stimulation of 3H-AA release from A7r5 cells (Figs.
1B and C), with no detectable formation of 3H-PA
(Fig. 1A). The response was slightly more sensitive to AVP
than were Ca2+ release and regulation of Ca2+ entry (EC50
20 nM [5,6,28]). The diﬀerence would be consistent with
3H-AA release lying downstream of the Ca2+ signal. During
sustained exposure to AVP the rate of 3H-AA release declined,
but comparison of the responses to brief (3 min) and sustained
(9 min) additions shows that the eﬀect of AVP was both revers-
ible and persisted for at least 9 min (Fig. 1B). U73122 (1 lM),
a selective inhibitor of phospholipase C [30], abolished AVP-0 2 4 6 8
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Fig. 2. AVP-stimulated release of 3H-AA requires an increase in [Ca2+]i. (A
(1 lM, bar) alone (h) or in the presence of nimodipine (100 nM, n) or verapm
bar) in the presence (s) and absence (d) of extracellular Ca2+. (C) Ionomyc
stimulate 3H-AA release. (D) In cells pretreated with thapsigargin and iono
(1.5 mM, bar) stimulates 3H-AA release (s), which is blocked by 2-APB (10
normal HBS in control cells (s) or after loading with BAPTA (d, 50 lM Bevoked 3H-AA release (Fig. 1D). The half-maximal eﬀect of
U73122 (IC50 0.5 lM) is similar to that reported previously
(1 lM) for inhibition of AVP-evoked Ca2+ signals [5].
RHC 80267, an inhibitor of DAG lipase [31], only slightly
inhibited AVP-evoked 3H-AA release (Fig. 1E) and only at a
concentration (150 lM) greater than that required to abolish
the reciprocal eﬀects of AVP on Ca2+ entry pathways
(50 lM [5]). These results establish that most of the AVP-
evoked 3H-AA release detected in our assay is not the
product of DAG-lipase activity, but it requires activation of
PLC.
L-type Ca2+ channels contribute only modestly to the Ca2+
signals evoked by AVP [28], but their inhibition by nimodipine
(100 nM) or verapamil (10 lM) decreased the peak AVP-stim-
ulated rate of 3H-AA release by 31 ± 12% and 43 ± 12%,
respectively (Fig. 2A). Nimodipine (100 nM) was included in
all subsequent experiments to block any contribution from
voltage-gated Ca2+ entry, which earlier work had shown to
be entirely mediated by L-type Ca2+ channels [6].
This partial inhibition of AVP-evoked 3H-AA release by
inhibition of L-type Ca2+ channels and a further considerable0 2 4 6 8
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il (10 lM, s). (B) 3H-AA release during stimulation with AVP (1 lM,
in and thapsigargin (1 lM each, bar) in Ca2+-free medium transiently
mycin to empty intracellular stores, restoration of extracellular Ca2+
0 lM, d). (E) Stimulation of 3H-AA release by AVP (100 nM, bar) in
APTA-AM for 2 h). Traces are means ± S.E.M., n = 3.
Y. Liu, C.W. Taylor / FEBS Letters 580 (2006) 4114–4120 4117reduction when extracellular Ca2+ was removed (Fig. 2B) sug-
gest that an increase in [Ca2+]i may stimulate
3H-AA release.
In the absence of extracellular Ca2+, thapsigargin and ionomy-
cin released Ca2+ from intracellular stores and stimulated 3H-
AA release (Fig. 2C). Restoration of extracellular Ca2+ to cells0 2 4 6 8
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Fig. 3. AVP-stimulated release of 3H-AA is mediated by cPLA2. (A)
3H-AA
0.5 lM (s) or 50 lM (d) ONO-RS-082. (B) Concentration dependent eﬀects
3H-AA release evoked by thapsigargin/ionomycin (1 lM of each, bar) alone (d
AA release alone (d) or in the presence of BEL (10 lM, s); response in the a
the presence of AACOCF3 (200 lM,s). Inset shows eﬀects of indicated conce
response observed with AVP alone). (F) Ca2+ signals evoked by AVP (100
(20 lM), BEL (10 lM) or ONO-RS-082 (50 lM). Ca2+ signals recorded with
experiments, inhibitors were present for 5 min before and then during the adwith empty intracellular stores also stimulated 3H-AA release
(Fig. 2D). The latter, CCE-evoked stimulation of 3H-AA re-
lease, was inhibited by 2-APB (Fig. 2D). These results demon-
strate that release of Ca2+ from intracellular stores or Ca2+
entry via CCE or L-type Ca2+ channels stimulates 3H-AA-10 -8 -6 -40.1
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dition of AVP. Results are means ± S.E.M., n = 3 (A, C–F) or 4 (B).
AVP
PLCPLD
PA DAG + IP3
Ca2+
cPLA2
AA
U73122
BAPTA
AACOCF3
ONO-RS-082
BEL
ONO-RS-082
Butan-1-ol
PAP
PKC
DAG
lipase
PC
DAG
SFK
PYK2
P
Kv
L-type
channel
Ca2+ spiking
RHC 80267
PE
ER
PM
AVP
≤1nM ≥1nM
PIP2
AA
Fig. 4. Stimulation of phospholipid turnover and Ca2+ signalling by
AVP. Low concentrations of AVP activate PLD leading to increased
Ca2+ spiking. Higher concentrations of AVP stimulate PLC and so
both IP3-mediated release of Ca
2+ from intracellular stores and Ca2+
entry. The resulting Ca2+ signals activate cPLA2 with consequent
release of AA from PE. AA released from DAG derived from PLC has
earlier been shown to reciprocally regulate Ca2+ entry pathways,
whereas AA derived from PLA2 is ineﬀective. Nor is there any evidence
to suggest that DAG derived from PLD serves as a substrate for DAG
lipase (dashed grey lines). Enzymes are shown boxed, their inhibitors
with hammerheads, and substrate-products with kinked arrows.
PYK2, proline-rich tyrosine kinase 2; SFK, src family kinase; PAP,
PA phosphohydrolase.
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which the intracellular Ca2+ stores had been emptied by prior
treatment with thapsigargin and ionomycin (not shown). In
cells loaded with the fast Ca2+-buﬀer, 1,2-bis(2-aminophen-
oxy)ethane-N,N,N 0N 0-tetraacetic acid (BAPTA), by prior incu-
bation with BAPTA-AM, AVP caused no detectable increase
in [Ca2+]i [28] and no release of
3H-AA (Fig. 2E) even
in Ca2+-containing HBS. These results establish that most
3H-AA release evoked by AVP in A7r5 cells is mediated by
an increase in [Ca2+]i.
ONO-RS-082, an inhibitor of many isoforms of PLA2,
caused a complete and concentration-dependent
(IC50 = 0.44 lM) inhibition of AVP-evoked
3H-AA release
(Figs. 3A, B), and likewise completely inhibited the 3H-AA re-
lease evoked by ionomycin and thapsigargin (Fig. 3C). These
results showing inhibition of 3H-AA release by ONO-RS-082
diﬀer from a previous analysis, in which ONO-RS-082 inhibited
PLD, and so release of 3H-AA-labelled PA, but not release of
3H-AA [17]. During our briefer assay periods (60 s vs 27 min)
with higher concentrations of AVP (100 nM vs 0.1 nM) we de-
tected no release of 3H-AA-labelled PA (Fig. 1A), but much lar-
ger increases in 3H-AA release (300% vs <10%) (Fig. 1).
Stimulation of A10 vascular smooth muscle cells with 1 lM
AVP likewise caused release of only 3H-AA [25].
BEL, a selective and irreversible inhibitor of Ca2+-indepen-
dent PLA2 (iPLA2) [25,26], did not inhibit AVP-evoked
3H-
AA release; indeed at 10 lM BEL signiﬁcantly potentiated
the response (Fig. 3D). Phosphatidic acid (PA) phosphohydro-
lase, which catalyses formation of DAG from PA (Fig. 4), is
also inhibited by BEL and with similar sensitivity to inhibition
of iPLA2 [32]. The lack of inhibition of AVP-evoked
3H-AA
release by BEL (Fig. 3D) argues that DAG derived from PA
(Fig. 4), which is a major route for PA metabolism in A7r5
cells [24], is unlikely to contribute signiﬁcantly to the 3H-AA
release. That conclusion is consistent also with our observation
that inhibition of DAG lipase fails signiﬁcantly to inhibit
AVP-evoked 3H-AA release (Fig. 1E).
AACOCF3 (620 lM), an inhibitor of both iPLA2 and cyto-
solic PLA2 (cPLA2) (though not sPLA2s) [33,34] substantially
inhibited AVP-evoked 3H-AA release (Fig. 3E). The lowest
concentration of AACOCF3 (0.2 lM, Fig. 3E inset), like all
eﬀective concentrations of BEL (Fig. 3D), modestly enhanced
AVP-evoked 3H-AA release. This eﬀect may perhaps result
from the shared abilities of BEL and AACOCF3 to inhibit
iPLA2 and might thereby suggest that iPLA2 activity attenu-
ates the ability of AVP to evoke cPLA2-mediated AA release.
None of the PLA2 inhibitors aﬀected the Ca
2+ signals evoked
by AVP (Fig. 3F).4. Discussion
The concentration-dependent stimulation of 3H-AA release
by AVP requires activation of PLC (Fig. 1D), an increase in
[Ca2+]i (Fig. 2) and activation of cPLA2 (Fig. 3). The latter
is known to be both Ca2+-stimulated and selective for sn-2
arachidonyl phospholipids [35]. Release of Ca2+ from intracel-
lular stores, whether evoked by IP3 (Fig. 2B) or thaspsigargin/
ionomycin (Fig. 2D), and Ca2+ entry via CCE (Fig. 2D) or L-
type Ca2+ channels (Fig. 2A) are each capable of contributing
to the Ca2+ signals that stimulate 3H-AA release, suggestingthat an increase in [Ca2+]i is both necessary and suﬃcient for
activation of cPLA2 in A7r5 cells. The ability of Ca
2+ entering
the cytosol via such diﬀerent routes to stimulate cPLA2 is con-
sistent with its a, b and c isoforms being cytosolic enzymes that
redistribute to perinuclear membranes when Ca2+ binds to
their C2 domains [22], and with evidence that norepinephrine
causes Ca2+-dependent translocation of cPLA2 to the nuclear
envelope in aortic smooth muscle [36]. Our results are, how-
ever, diﬀerent from those obtained in A10 cells, close relatives
of A7r5 cells [37], where 70% of the 3H-AA released in re-
sponse to AVP was inhibited by BEL [25] and likely therefore
to be mediated by iPLA2. Growth factors stimulate expression
of cPLA2 in vascular smooth muscle [19,38]. The much re-
duced expression of cPLA2 in non-proliferating smooth muscle
cells may account for the diﬀerent contributions from iPLA2
and cPLA2 in diﬀerent studies. We used subconﬂuent cultures
of A7r5 cells maintained in serum (see Section 2), whereas oth-
ers used conﬂuent cells deprived of serum [14,39].
We have not addressed the role of AVP in stimulating PLD
in A7r5 cells: 3H-AA would be a poor tracer for such an
analysis because only a tiny fraction of the phospholipids
hydrolyzed by PLD contain AA [40] and most of the PA pro-
duced might be expected to remain within cells [24] and so
evade detection in our assay. Others have shown that low con-
centrations of AVP stimulate PLD and that it provides an
essential link between AVP and Ca2+ spiking mediated by L-
Y. Liu, C.W. Taylor / FEBS Letters 580 (2006) 4114–4120 4119type Ca2+ channels [17,18]. Both BEL and ONO-RS-082 inhib-
ited Ca spiking, and ONO-RS-082 was shown also to inhibit
PLD, but not the Ca2+ signals evoked by higher concentra-
tions of AVP [17]. The latter is consistent with our results
(Fig. 3F). The important points are that in our measurements
of the eﬀects of higher concentrations of AVP on 3H-AA re-
lease, we detect no 3H-PA formation (Fig. 1A); 3H-AA release
is entirely Ca2+-dependent, whereas neither of the PLD iso-
forms expressed in A7r5 cells is known to be Ca2+-regulated
[41]; we ﬁnd no evidence for release of 3H-AA from DAG
(Fig. 1E); and, as discussed above, the inhibitory eﬀect of
ONO-RS-082 is consistent with inhibition of cPLA2. We con-
clude that concentrations of AVP that stimulate PLC also
stimulate AA release and this occurs primarily via a Ca2+-
dependent activation of cPLA2.
Fig. 4 summarizes our conclusions and their possible rela-
tionship with earlier work. At low concentrations (61 nM),
AVP stimulates Ca2+ spiking mediated by L-type Ca2+ chan-
nels: the likely steps in this sequence have been identiﬁed by
Byron and colleagues and are shown in Fig. 4 [17,18]. Phos-
phatidylcholine (PC) probably provides the major substrate
for the PLD that initiates this sequence [42], but the links be-
tween the V1A receptors and stimulation of PLD remain to be
identiﬁed [17]. Higher concentrations of AVP (P 1 nM,
Fig. 1C) stimulate PLC and the resulting Ca2+ signals stimu-
late cPLA2 and so release of AA. Phosphatidylethanolamine
(PE) is the most likely source of this AA because although it
and PC are the phospholipids in aortic smooth muscle that
are most enriched in AA, Ca2+-mobilizing stimuli have been
shown preferentially to release AA from PE [43].
An intriguing feature of our results is the extent to which sig-
nals, notably DAG and AA, appear to evoke diﬀerent re-
sponses when produced by diﬀerent signalling pathways.
DAG produced via the PLD pathway, for example, seems
eﬀectively to regulate the PKC that leads to enhanced Ca2+
spiking [18], without apparently causing PKC-mediated desen-
sitization to AVP [5], and nor does this DAG appear to pro-
vide a suitable substrate for DAG lipase-mediated release of
AA [6]. AA appears also to diﬀer in its eﬀectiveness according
to how it is produced. We have shown earlier that release of
AA by DAG lipase from DAG produced by AVP-activated
PLC causes reciprocal regulation of CCE and NCCE [6,7],
but the much larger amounts of AA produced by cPLA2
(Fig. 1) appear not to signiﬁcantly inﬂuence Ca2+ entry
(Fig. 3F). The mechanisms underlying these phenomena are
not yet deﬁned, but we speculate that subcellular compartmen-
talization of these related signalling pathways may be impor-
tant in allowing similar messengers to be directed to diﬀerent
targets.
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